0000950170-24-024986.txt : 20240304
0000950170-24-024986.hdr.sgml : 20240304
20240304172956
ACCESSION NUMBER: 0000950170-24-024986
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240304
DATE AS OF CHANGE: 20240304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mylet Johanna
CENTRAL INDEX KEY: 0001765988
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39376
FILM NUMBER: 24716296
MAIL ADDRESS:
STREET 1: C/O POSEIDA THERAPEUTICS, INC.
STREET 2: 4242 CAMPUS POINT COURT, SUITE 700
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Poseida Therapeutics, Inc.
CENTRAL INDEX KEY: 0001661460
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 472846548
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9390 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-779-3100
MAIL ADDRESS:
STREET 1: 9390 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
ownership.xml
4
X0508
4
2024-03-01
false
0001661460
Poseida Therapeutics, Inc.
PSTX
0001765988
Mylet Johanna
C/O POSEIDA THERAPEUTICS, INC.
9390 TOWNE CENTER DRIVE SUITE 200
SAN DIEGO
CA
92121
false
true
false
false
Chief Financial Officer
false
Common Stock
2024-03-01
4
A
false
80743
0.00
A
264374
D
Common Stock
2024-03-01
4
F
false
18091
4.13
D
246283
D
Employee Stock Option (Right to Buy)
4.13
2024-03-01
4
A
false
111700
0.00
A
2034-02-28
Common Stock
111700
111700
D
Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on March 20, 2023 and 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2023.
Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on March 1, 2022 and March 1, 2023.
12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.
/s/ Harry J.Leonhardt, Attorney-in-Fact
2024-03-04